FOXO1 has also been shown to bind and inhibit the transcriptional activity of E26 transformation-specific (ETS) transcription factor ERG, which is over-expressed in 50% of prostate cancers owing to TMPRSS2-ERG (transmembrane protease, serine 2: ERG fusion) gene rearrangements [162]. This evidence concerns the gene FOXO1 and Familial prostate cancer.